All Perspectives, One Place.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Artificial Intelligence
Social Media
Stock Markets
Natural Disasters
Donald Trump
Baseball
Senate
Cryptocurrency
Immigration
Innovation
Education
Housing
Published • loading... • Updated

Savolitinib Combo Prolongs PFS in Pretreated EGFR+ NSCLC

Summary by cancernetwork.com
Data from SACHI support savolitinib/osimertinib as a chemotherapy-free option in previously treated EGFR-mutated NSCLC harboring a MET amplification.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
targetedonc.comtargetedonc.com

SACHI Trial: Savolitinib/Osimertinib Improves PFS in MET-Amplified NSCLC

The SACHI trial showed savolitinib + osimertinib significantly improved PFS (8.2 vs 4.5 months) vs chemotherapy in EGFR-mutated, MET-amplified advanced NSCLC after EGFR TKI progression.

Read Full Article
cancernetwork.comcancernetwork.com

Savolitinib Combo Prolongs PFS in Pretreated EGFR+ NSCLC

Data from SACHI support savolitinib/osimertinib as a chemotherapy-free option in previously treated EGFR-mutated NSCLC harboring a MET amplification.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

cancernetwork.com broke the news in on Sunday, June 1, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States

United States

News
For You
SearchBlindspotLocal